Search Results - Jennifer A. Low

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
    Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy

    Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy by Jennifer A. Low, Arlene Berman, Seth M. Steinberg, David N. Danforth, Marc E. Lippman, Sandra M. Swain

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

    A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fluda... by Judith E. Karp, Francis J. Giles, Ivana Gojo, Lawrence E. Morris, Jacqueline M. Greer, Bonny Johnson, Mya Thein, Mario Sznol, Jennifer A. Low

    Published 2007
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes

    Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes by Neelima Denduluri, Jennifer A. Low, James J. Lee, Arlene Berman, Janice M. Walshe, Ujala Vatas, Catherine K. Chow, Seth M. Steinberg, Sherry Yang, Sandra M. Swain

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects

    Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects by Richard Graham, Cornelis E. C. A. Hop, Marie T. Borin, Bert L. Lum, Dawn Colburn, Ilsung Chang, Young G. Shin, Vikram Malhi, Jennifer A. Low, Mark J. Dresser

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

    Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding by Richard Graham, Bert L. Lum, Sravanthi Cheeti, Jin Y. Jin, Karin Jorga, Daniel D. Von Hoff, Charles M. Rudin, Josina C. Reddy, Jennifer A. Low, Patricia LoRusso

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors

    Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors by Patricia LoRusso, Antonio Jimeno, Grace K. Dy, Alex A. Adjei, Jordan Berlin, Lawrence Leichman, Jennifer A. Low, Dawn Colburn, Ilsung Chang, Sravanthi Cheeti, Jin Y. Jin, Richard Graham

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Influence of Garlic (<i>Allium sativum</i>) on the Pharmacokinetics of Docetaxel

    Influence of Garlic (<i>Allium sativum</i>) on the Pharmacokinetics of Docetaxel by Michael C. Cox, Jennifer A. Low, James Lee, Janice M. Walshe, Neelima Denduluri, Arlene Berman, Matthew G. Permenter, William P. Petros, Douglas K. Price, William D. Figg, Alex Sparreboom, Sandra M. Swain

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer

    A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer by Jordan Berlin, Johanna C. Bendell, Lowell L. Hart, Irfan Firdaus, Ira Gore, Robert C. Hermann, Mary F. Mulcahy, Mark M. Zalupski, Howard Mackey, Robert L. Yauch, Richard Graham, Gordon L. Bray, Jennifer A. Low

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

    Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449 by Charles M. Rudin, Christine L. Hann, John Laterra, Robert L. Yauch, Christopher A. Callahan, Ling Fu, Thomas Holcomb, Jeremy Stinson, Stephen E. Gould, Barbara Coleman, Patricia LoRusso, Daniel D. Von Hoff, Frédéric J. de Sauvage, Jennifer A. Low

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

    Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors by Patricia LoRusso, Charles M. Rudin, Josina C. Reddy, Raoul Tibes, Glen J. Weiss, Mitesh J. Borad, Christine L. Hann, Julie R. Brahmer, Ilsung Chang, Walter C. Darbonne, Richard Graham, Kenn L. Zerivitz, Jennifer A. Low, Daniel D. Von Hoff

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    An Oncogenic <i>NTRK</i> Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

    An Oncogenic <i>NTRK</i> Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101 by Robert C. Doebele, Lara E. Davis, Aria Vaishnavi, Anh T. Le, Adriana Estrada‐Bernal, Stephen B. Keysar, Antonio Jimeno, Marileila Varella‐Garcia, Dara L. Aisner, Yali Li, Philip J. Stephens, Deborah Morosini, Brian B. Tuch, Michele Fernandes, Nisha Nanda, Jennifer A. Low

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

    Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma by Daniel D. Von Hoff, Patricia LoRusso, Charles M. Rudin, Josina C. Reddy, Robert L. Yauch, Raoul Tibes, Glen J. Weiss, Mitesh J. Borad, Christine L. Hann, Julie R. Brahmer, Howard Mackey, B. Lum, Walter C. Darbonne, James C. Marsters, Frédéric J. de Sauvage, Jennifer A. Low

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

    Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma by Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro, Luc Dirix, Karl D. Lewis, John D. Hainsworth, James Solomon, Simon Yoo, Sarah T. Arron, Philip Friedlander, Ellen S. Marmur, Charles M. Rudin, Anne Lynn S. Chang, Jennifer A. Low, Howard Mackey, Robert L. Yauch, Richard Graham, Josina C. Reddy, Axel Hauschild

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    <i>Smoothened</i> Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

    <i>Smoothened</i> Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma by Robert L. Yauch, Gerrit J.P. Dijkgraaf, Bruno Alicke, Thomas Januario, Christina P. Ahn, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Christopher A. Callahan, Tracy Tang, J. Fernando Bazán, Zhengyan Kan, Somasekar Seshagiri, Christine L. Hann, Stephen E. Gould, Jennifer A. Low, Charles M. Rudin, Frédéric J. de Sauvage

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer

    Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer by Suparna Wedam, Jennifer A. Low, Sherry X. Yang, Catherine K. Chow, Peter L. Choyke, David N. Danforth, Stephen M. Hewitt, Arlene Berman, Seth M. Steinberg, David J. Liewehr, Jonathan F. Plehn, Arpi Doshi, Dave Thomasson, Nicole McCarthy, Hartmut Koeppen, Mark E. Sherman, JoAnne Zujewski, Kevin Camphausen, Helen Chen, Sandra M. Swain

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

    Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies by Shivaani Kummar, Robert J. Kinders, Martin Gutierrez, Larry Rubinstein, Ralph E. Parchment, Lawrence R. Phillips, Jiuping Ji, Anne Monks, Jennifer A. Low, Alice P. Chen, Anthony J. Murgo, Jerry M. Collins, Seth M. Steinberg, Helen Eliopoulos, Vincent L. Giranda, Gary Gordon, Lee J. Helman, Robert H. Wiltrout, Joseph E. Tomaszewski, James H. Doroshow

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: